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Abstract
The current standard biomarker for myocardial infarction (MI) is high-sensitive tro-
ponin. Although powerful in clinical setting, search for new markers is warranted as 
early diagnosis of MI is associated with improved outcomes. Extracellular vesicles 
(EVs) attracted considerable interest as new blood biomarkers. A training cohort used 
for diagnostic modelling included 30 patients with STEMI, 38 with stable angina (SA) 
and 30 matched-controls. Extracellular vesicle concentration was assessed by na-
noparticle tracking analysis. Extracellular vesicle surface-epitopes were measured 
by flow cytometry. Diagnostic models were developed using machine learning algo-
rithms and validated on an independent cohort of 80 patients. Serum EV concentra-
tion from STEMI patients was increased as compared to controls and SA. EV levels of 
CD62P, CD42a, CD41b, CD31 and CD40 increased in STEMI, and to a lesser extent 
in SA patients. An aggregate marker including EV concentration and CD62P/CD42a 
levels achieved non-inferiority to troponin, discriminating STEMI from controls 
(AUC = 0.969). A random forest model based on EV biomarkers discriminated the 
two groups with 100% accuracy. EV markers and RF model confirmed high diagnostic 
performance at validation. In conclusion, patients with acute MI or SA exhibit char-
acteristic EV biomarker profiles. EV biomarkers hold great potential as early markers 
for the management of patients with MI.
K E Y W O R D S
acute myocardial infarction, biomarker, coronary artery disease, extracellular vesicles, 
machine learning, ST-segment elevation myocardial infarction
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1  | INTRODUC TION
Coronary artery disease is the most frequent cause of death world-
wide.1 Among acute coronary syndromes, ST-segment elevation 
myocardial infarction (STEMI) is associated with a 12%-mortality 
within 6 months.2 Early diagnosis of myocardial infarction (MI) is 
critical to preserve cardiac function and improve outcomes.3,4 This 
diagnosis currently relies on chest pain suggestive of myocardial 
ischemia, specific electrocardiogram (ECG) changes, and detection 
of increased serum levels of high-sensitive (hs) troponin,4 which is 
released within 2-3 hours after the onset of cardiac injury. Although 
extremely useful in a daily clinical setting, a search for novel bio-
markers to identify patients with MI early after onset of symptoms, 
when primary percutaneous coronary intervention (PCI) has the 
greatest chance of influencing their outcomes, is warranted.5,6
Emerging potential biomarkers for coronary artery disease (CAD) 
include secreted extracellular vesicles (EVs), which are found in all bi-
ological fluids including peripheral blood.6-8 Their diagnostic power 
derives from the enrichment of potential protein markers which oth-
erwise constitute only a very small proportion (<0.01%) of the total 
proteome of body fluids.9 EVs can be subdivided into exosomes, which 
originate from the endosomal system, and microvesicles, which di-
rectly shed by plasma membranes. Traditionally, EVs were subdivided 
by size: small EVs (30 nm-150 nm in diameter) mainly consisting of 
exosomal EVs, and medium-large EVs (150 nm-1000 nm in diameter) 
mainly representing microvesicles. Some EV cargo proteins specify a 
cellular origin or change in amount in certain diseases, so that they can 
serve as biomarkers of diseases. Exosomal surface epitopes include the 
tetraspanins CD9, CD63, and CD81. Intra-vesicular exosomal markers 
include tumour susceptibility gene 101 (TSG101).6,10
Most circulating EVs in healthy individuals are derived from 
platelets and erythrocytes; however, vesicles also are released from 
leucocytes, endothelial cells, monocytes, neutrophils and lympho-
cytes.7,11 Previous studies have shown increased numbers of plate-
let, endothelial cell- and leucocyte-derived EVs in patients with 
acute coronary syndromes (ACS) or chronic CAD.12-23 However, par-
tially divergent results have been reported, in part due to method-
ological differences in EV isolation.24,25 Moreover, previous analyses 
focused on a few surface epitopes of interest, rather than on the EV 
epitope surface profile.
The main potential advantage of EV profiling in the management 
of patients with CAD is represented by the very early increase of 
circulating particles released by suffering but still alive cardiomyo-
cytes, during heart ischemia.6,22 Indeed, the increase in EV-derived 
biomarkers may even anticipate the raise of hs-troponin, which 
need cardiomyocytes death. However, EV profiling needs for pro-
tocol standardization and technology implementation, and that this 
approach remains to date relatively time-consuming and expensive 
when compared to troponin.6 Potential advantages and disadvan-
tages of EV profiling as compared to hs-troponin in the management 
of patients with CAD are summarized in Table S1.
In the present study, we analysed a comprehensive panel of 37 
EV surface epitopes, representative of a variety of cells of origin, in 
serum samples from patients with acute MI and patients with chronic 
CAD presenting with stable angina (SA), compared to age- and sex-
matched healthy controls, using a validated multiplex flow cytome-
try (FC) assay.25,27 A random forest (RF) model based on EV surface 
epitopes accurately discriminated STEMI patients and controls.
2  | METHODS
A detailed description of patient data, EV extraction and characteri-
zation protocols, statistical analyses and diagnostic modelling is pro-
vided in the Appendix S1.
2.1 | Participants and blood sampling
We analysed peripheral venous blood samples collected from in-
dividuals recruited at the Fondazione Cardiocentro Ticino, Lugano 
(Switzerland), as a training cohort for diagnostic modelling purposes. 
An independent cohort enrolled at Città della Salute e della Scienza, 
University of Torino (Italy), served as validation cohort. The study 
protocol was approved by the local ethical committees. All partici-
pants gave informed written consent to the study in accordance with 
the declaration of Helsinki. Peripheral venous blood samples were 
collected from patients presenting with a diagnosis of STEMI, ac-
cording to the European Society of Cardiology (ESC) guidelines,4 on 
presentation to the emergency department before primary PCI, as 
well as 24 hours (hours) and 48 hours thereafter. Exclusion criteria 
included: (a) Chest pain onset ≥6 hours; (b) Age > 85; (c) Cardiac ar-
rest or cardiogenic shock with indication to invasive device assis-
tance; (d) Glomerular filtration rate <30 mL/min; (e) Atrial fibrillation, 
ventricular tachycardia, ventricular fibrillation or other arrhythmias 
requiring defibrillation; (f) Non-ischemic heart disease such as severe 
heart valve disease, chronic heart failure and other heart diseases 
with impaired left ventricular ejection fraction (LVEF); (g) Acute or 
chronic inflammatory diseases (eg auto-immune disease, cancer and 
infections). In addition, samples were collected from patients with 
chronic CAD presenting with SA according to ESC guidelines,28 with 
angiographically documented coronary stenoses (≥70% internal ves-
sel diameter reduction). Asymptomatic subjects who underwent 
64-slice multidetector computed tomography of coronary arteries 
for primary prevention purposes and had documented absence of 
coronary stenoses (ie >30% diameter reduction), were enrolled as 
controls. The aforementioned exclusion criteria also applied to SA 
patients and controls. Unblinded investigators were responsible for 
identifying participants but were not involved in any experimental 
procedures.
2.2 | Sample processing
Blood was collected in 7 mL heparin- and EDTA-free polypropylene 
tubes. The first blood tube was discarded. Blood was centrifuged 
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at 1600 g for 15 minutes at 4°C, and supernatant was centrifuged 
at 3000 g for 20 minutes, 10 000 g for 15 minutes and 20 000 g 
for 30 minutes to remove intact cells, cellular debris and larger EVs 
(apoptotic bodies and EV aggregates; see also Extended Methods 
and Figure S1A). After centrifugation steps, supernatant was divided 
into 0.1 mL aliquots and stored at −80°C until analysis. Pre-analytical 
factors for blood collection and storage complied with guideline for 
EV biomarkers.6
2.3 | Western blot analysis
Western blot analysis was performed on 100 μL of serum samples 
incubated overnight with MACSPlex capture beads. Next day, the 
unbounded fraction was discarded, and samples were lysed with 
RIPA Buffer. Total proteins (15 μg) were separated on SDS Page 4%-
12% gel (BioRad) and transferred onto PVDF membrane. The blot 
was incubated with the following primary antibody: Rabbit monoclo-
nal anti-TSG101 (ab125011 Abcam); mouse monoclonal anti-CD81 
(MA5-17937 Invitrogen); rabbit polyclonal anti-apolipoprotein A1 
(ab33470 Abcam) and rabbit polyclonal anti-apolipoprotein B48 
(ab31992 Abcam).
2.4 | Nanoparticle tracking analysis (NTA)
To measure serum particle concentration and diameter, we used 
NTA with NanoSight LM10 (Malvern Instruments) equipped with 
a 405 nm laser and NTA 2.3 analytic software. EV concentration 
is shown as particle number/mL (median value and interquartile 
range).
2.5 | EV surface epitope analysis
Serum samples underwent bead-based EV immunocapture 
and were analysed by FC using MACSPlex human Exosome 
Kit (Miltenyi; Bergisch Gladbach, Germany), as detailed in the 
Appendix S1 (see also Figure S1A). Briefly, serum supernatant 
was incubated with 37 fluorescently labelled capture bead popu-
lations (Table S2), each coated with a specific antibody binding 
the respective surface epitope, and 2 control bead populations, 
followed by the EV detection reagent (ie fluorescently labelled 
antibodies for CD9/CD63/CD81). Median fluorescence intensity 
(MFI) was measured on a MACSQuant-Analyzer-10 flow cytom-
eter (Miltenyi) according to previous validation studies.26,27 All 
markers were analysed simultaneously. Surface epitope levels 
were referenced to EV-specific epitopes by subtracting the re-
spective fluorescence values of blank control from MFI values for 
individual surface epitopes, and by normalizing them for CD9/
CD63/CD81 MFI, reflecting EV concentration. To rule out con-
founding effects of the protocol used, this method was compared 
with alternate protocols in a small subset of patients. Specifically, 
the effect of EV isolation by ultracentrifugation or size-exclusion 
chromatography (SEC) was assessed (Figure S2A,B). Moreover, EV 
markers were determined in both serum and plasma samples from 
the same patients (Figure S2C and S3). A shortened incubation 
time (1 hour) of serum supernatant with capture beads was tested 
as compared to overnight incubation (Figure S2D). Finally, techni-
cal reproducibility of the assay was confirmed by analysing twice 
the same sample (Figure S4).
2.6 | Statistical analysis and diagnostic modelling
IBM SPSS Statistics 22 (IBM), Python 3.5 (library, scikit-learn) and 
GraphPad PRISM 7.0a were used for statistical analyses. ANOVA 
with post hoc Bonferroni's test and Kruskal-Wallis's test was used to 
compare variables with a normal or non-normal distribution, respec-
tively. Categorical variables were compared through a chi-square 
test. Correlations were evaluated by Pearson's test and regres-
sion curve analyses. The analysis of receiver operating character-
istics (ROC) curves was used to compare diagnostic performances 
of selected variables. Multivariate logistic regression analysis was 
performed to determine odds ratio (ORs). P-values < .05 were con-
sidered significant.
Supervised machine learning algorithms and in particular linear 
discriminant analysis (LDA) and random forest (RF) models have been 
exploited in the context of diagnostic modelling for clinical research, 
as described previously.29,30 LDA was used as a strategy for feature 
reduction to build the canonical plot. Diagnostic models were built 
through a RF classification algorithm; the algorithm created 20 dif-
ferent classification trees and the predicted diagnosis resulted from 
the outcome of each tree of the forest. Diagnostic performance and 
generalizability of the models developed in the training cohort were 
validated in an independent cohort.
3  | RESULTS
3.1 | Clinical and biochemical characteristics of the 
study cohorts
We analysed 238 serum samples collected from 178 participants 
from a training cohort (n = 98) and an independent validation co-
hort (n = 80). The training cohort was divided into 3 groups (STEMI: 
n = 30, mean [SD] age, 63 [12.5] years; 6 women [20.0%]; SA: 
n = 38, mean [SD] age, 65 [8.9] years; 9 women [23.7%]; controls: 
n = 30, mean [SD] age, 60 [9.8] years; 12 women [40.0%]; Table 1). 
Dyslipidemia (48.0%) and hypertension (43.9%) were highly prev-
alent in the study population, followed by smoking (14.3%), dia-
betes (12.2%) and chronic kidney disease (5.1%). Study groups did 
not significantly differ from one another with respect to age, sex, 
body weight, body-mass index, prevalence of cardiovascular risk 
factors, systolic and diastolic blood pressure, renal function, lipid 
profile and glucose levels. STEMI patients significantly differed 
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from SA patients and controls only with respect to hs-troponin, 
white blood cells (WBC), C-reactive protein (CRP) and left ven-
tricular ejection fraction (LVEF) assessed by echocardiography 
<24 hours post-PCI. Infarcted myocardial regions and culprit ves-
sels are described in Table S3. The time interval (median [range]) 
between onset of chest pain and blood sampling in STEMI pa-
tients was 2.75 [2.0-4.0] hours. Pharmacological treatment at the 
enrolment was not significantly different between groups (Table 
S4). Based on the results in the training cohort, EV markers were 
validated for the diagnosis of STEMI, in an independent cohort. 
Clinical and biochemical characteristics of patients in the valida-
tion cohort did not significantly differ from the training cohort 
(Table S5). Except for cardiac-specific hs-troponin I, WBC counts 
and LVEF, patients' characteristics were not significantly differ-
ent in STEMI patients and controls in the validation cohort (Table 
S6).
3.2 | EV number and size
Serum samples were pre-cleared by serial centrifugation steps in 
order to remove intact cells, cellular debris and larger EVs, while 
enriching in smaller particles. EV number and diameter decreased 
after each centrifugation step, showing a trend to depletion of 
particles larger than 250 nm (P > .05; Figure S1B). Before per-
forming EV immunocapture, particle size and concentration were 
determined by NTA. In the training cohort, EV concentration 
measured by NTA was significantly increased in serum samples 
from STEMI patients on presentation to the emergency depart-
ment (Tables S7 and S8; median [interquartile range, IQR] con-
centration, 8.5e11 [4.0e11;1.6e12] compared with SA patients 
(3.8e11 [2.2e11;7.9e11]) and controls (2.1e11 [1.5e11;4.7e11], 
P < .001; Figure 1A,C,D). In STEMI patients, EV concentration 
declined at 24 hours and 48 hours. A significant difference in 
TA B L E  1   Clinical and biochemical characteristics (training cohort)










Age (y) 60 ± 9.8 63 ± 12.5 65 ± 8.9 .219 – – –
Sex (ref. male) 18 (60.0) 24 (80.0) 29 (76.3) .176 – – –
Familiarity for CAD 
(%)
11 (36.7) 6 (20.0) 15 (39.5) .201 – – –
Hypertension (%) 9 (30.0) 13 (43.3) 21 (55.3) .114 – – –
Diabetes (%) 1 (3.3) 4 (13.3) 7 (18.4) .165 – – –
Dyslipidemia (%) 12 (40.0) 14 (46.7) 21 (55.3) .451 – – –
CKD (%) 2 (6.7) 2 (6.7) 1 (2.6) .676 – – –
Smoking Habit (%) 2 (6.7) 4 (13.3) 8 (21.1) .370 – – –
Systolic BP (mm Hg) 130 ± 14.1 134 ± 23.4 136 ± 17.2 .523 – – –
Diastolic BP (mm Hg) 81 ± 5.0 82 ± 14.7 79 ± 8.2 .714 – – –
Weight (kg) 75 ± 9.1 77 ± 14.9 79 ± 17.7 .619 – – –
BMI (kg/m2) 26.4 ± 3.27 26.3 ± 4.25 27.3 ± 5.4 .631 – – –
hs-troponin (ng/L) 8 ± 11.1 669 ± 1295.0 10 ± 14.6 .002 .012 1.000 .004
WBC (n/L) 7108 ± 2220.0 10 583 ± 2535.3 7439 ± 2244.9 <.001 <.001 1.000 <.001
Creatinine (mg/dL) 0.89 ± 0.236 0.95 ± 0.196 0.94 ± 0.152 .543 – – –
GFR (mL/min) 90 ± 14.3 88 ± 31.9 81 ± 29.8 .490 – – –
CRP (mg/L) 1.8 ± 0.78 7.6 ± 7.30 5.0 ± 5.38 .002 .001 .119 .161
Glycemia (mmol/L) 6.6 ± 2.56 8.3 ± 2.98 7.2 ± 2.59 .082 – – –
Total cholesterol 
(mmol/L)
4.8 ± 0.73 5.0 ± 1.47 4.5 ± 1.03 .283 – – –
HDL (mmol/L) 1.4 ± 0.42 1.6 ± 1.66 1.3 ± 0.46 .595 – – –
Triglycerides 
(mmol/L)
1.5 ± 1.18 1.5 ± 1.98 1.3 ± 0.65 .805 – – –
LVEF at echo (%) 62 ± 4.3 52 ± 8.4 60 ± 7.0 <.001 <.001 .614 <.001
Note: Clinical and biochemical characteristics of patients diagnosed with ST-segment elevation myocardial infarction (STEMI; n = 30) compared to 
controls (CTRL; n = 30) and patients with stable angina (SA; n = 38), who were enrolled in the training cohort. Data are expressed as mean ± SD, or 
absolute number (percentage), when appropriated. P-values < .05 were considered significant and indicated by bold characters.
Abbreviations: BP, Blood Pressure; CAD, Coronary Artery Disease; CKD, Chronic Kidney Disease; CRP, C-Reactive Protein; GFR, Glomerular 
Filtration Rate; LVEF, Left Ventricular Ejection Fraction at echocardiography; WBC, White Blood Cells.
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EV concentration was also found between SA patients and con-
trols (P < .05). Average EV size was similarly increased in STEMI 
patients, and to a lesser extent in SA patients (Figure 1B), as 
evidenced by a higher normalized area under the curve (AUC) 
for cumulative distribution curves (P < .001; Figure 1C,D). After 
stratification for particle diameter, STEMI patients on presenta-
tion to the emergency department showed an increase in both 
small (30-150 nm in diameter) and larger EVs (151-500 nm; 
P < .01 vs. controls), whereas SA patients exhibited an increase 
in small particles only (P < .05; Figure 1E). The time course of 
the increase in EV concentration and hs-troponin in the serum 
of STEMI patients is shown on Figure 1G. Particle concentration 
peaked on presentation to the emergency department and de-
clined by 24 hours and 48 hours, whereas hs-troponin peaked at 
24 hours.
3.3 | EV characterization and assay validation
The specificity of EV immuno-capture assay was assessed by 
Western blot and correlation analysis with NTA data. Presence 
of the exosomal markers TSG101 and CD81 after incubation with 
capture beads was demonstrated by Western blotting (Figure 
S1D,E). Apolipoproteins A1 and B48 were also detectable in these 
preparations, as expected, being reduced by up to 90% compared 
with the respective serum samples, suggesting a negligible lipo-
protein contamination. It should be noted, however, that the assay 
used for FC analysis, selectively measured EV surface epitopes of 
interest labelled with EV-specific markers (CD9, CD63 and CD81, 
tetraspanins generally accepted as EV surface markers), providing 
for an additional level of EV selectivity (Figure S1). In addition, 
the expression levels of tetraspanins at FC analysis were directly 
F I G U R E  1   Nanoparticle tracking 
analysis. Nanoparticle Tracking Analysis 
of circulating EVs in the three groups of 
patients of the training cohort (controls, 
CTRL vs stable angina, SA vs. STEMI 
pre-PCI and 24/48 h thereafter). (A) EV 
(extracellular vesicles) concentration; 
(B) EV diameter; (C and D) Cumulative 
distribution plot combining EV 
concentration (n/mL; y-axes) and diameter 
(nm; x-axes); (E) EV number stratified for 
EV diameter (30-150 nm vs 151-500 nm). 
(F) Mean fluorescence intensity (MFI) for 
CD9, CD63 and CD81 markers measured 
by flow cytometry. (G) EV concentrations 
and hs-troponin in Ctrl and STEMI 
patients at different time points. Data 
and statistical analysis: see Tables S7 
and S8. Data are shown as median and 
interquartile range. *P < .05; **P < .01
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correlated with EV concentration measured by NTA (R = 0.558; 
P < .001; Figure S1C). As expected, CD9/CD63/CD81 MFI as a 
measure of EV concentration was also increased in serum sam-
ples from STEMI patients compared with SA patients and controls 
(P < .001; Figure 1F). Separate experiments were performed to 
evaluate whether different protocols for EV isolation may affect 
expression EV surface antigens. After ultracentrifugation, we 
found a similar profile as compared with the standard immuno-
capture procedure described above, whereas the supernatant 
was relatively EV-depleted, as expected (Figure S2A). Similarly, 
EV isolation by SEC did not substantially affect EV marker pro-
files (Figure S2B). No difference was found comparing serum and 
plasma samples from the same patients (Figure S2C). EV marker 
profiles measured using 1-hour incubation of serum supernatant 
F I G U R E  2   Flow cytometric analysis of EV surface epitopes. Multiplex flow cytometry analysis. Median fluorescence intensities (MFI; 
[%]) for all EV epitopes, referenced to mean MFI of EV-specific markers (CD9, CD63 and CD81) in the training cohort. A, STEMI vs Ctrl. B, 
SA vs Ctrl. C, Heat map showing MFI for EV epitopes expressed at significantly higher levels in STEMI patients vs SA vs controls. Data and 
statistical analysis: see Table S9. Data are shown as median and interquartile range. *P < .05; **P < .01
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with capture beads were similar to those measured using over-
night incubation (Figure S2D). The low internal variability of our 
protocol was confirmed by analysing twice the same samples 
(Figure S4).
3.4 | EV surface epitopes
EV surface profiling was performed by FC analysis after bead-based 
immuno-capture according to the protocol shown above. EV surface 
epitope levels in STEMI patients, SA patients and controls are shown 
in Figure 2 and Tables S9 and S10. In each group, the two most highly 
expressed EV biomarkers were CD62P (P-selectin α-granule mem-
brane protein) and CD42a (platelet membrane glycoprotein), fol-
lowed by CD41b (platelet membrane glycoprotein II-b) and CD31 
(Platelet-Endothelial Cell Adhesion Molecule-1; PECAM-1). These 
EV epitopes, along with CD40 (antigen-presenting cells co-stimu-
latory receptor), were increased in STEMI patients on presentation 
to the emergency department (P < .001; Figure 2A). CD62P, CD42a 
and CD41b levels also were increased in SA patients vs. controls 
(P < .01; Figure 2B), albeit to a lesser extent than in STEMI patients 
(NS). CD31 and CD40 levels were significantly increased in STEMI 
patients vs. SA patients (P < .01). A heat map of EV surface epitopes 
in individual participants showed a clear clustering in STEMI patients 
(Figure 2C). Each of these markers (CD62P, CD42a, CD41b, CD31 
and CD40) correlated directly to peak hs-troponin and inversely to 
LVEF (Figure 3), which reflect cardiac injury. To assess the poten-
tial impact of the biological material, a comparative analysis of EV 
epitopes using plasma and serum samples from the same subjects 
was performed in a subset of patients. Each of the five markers that 
were significantly increased in STEMI patients at pre-PCI evaluation 
compared with controls using serum samples, remained significantly 
increased in STEMI patients using plasma samples (Figure S3). Thus, 
the results of this analysis in a subset of patients suggest no major 
impact of the choice of the biological fluid on EV marker analy-
sis. Finally, these five markers all declined over time in STEMI pa-
tients, whereas SSEA-4 (Stage-Specific-Embryonic Antigen-4) was 
not increased in these patients on presentation to the emergency 
F I G U R E  3   Correlations of EV markers 
to clinical parameters. Correlation 
of EV surface epitopes with clinical 
parameters in the training cohort. Left 
column: MFI (%) for the indicated EV 
epitopes, referenced to mean MFI 
for EV-specific markers (CD9, CD63, 
CD81) in different groups (bar graphs). 
Mid and right columns: correlations of 
MFI for EV epitopes to hs troponin and 
LVEF, respectively, in STEMI patients. 
Regression lines and 95% confidence 
intervals are shown. *P < .05; **P < .01
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department, whereas it was increased at 24 hours and 48 hours 
(P = .027 and P = .035, respectively; Figure S5).
3.5 | Performance of EV markers in STEMI 
discrimination
The diagnostic performance of EV concentration and EV surface 
markers in discriminating STEMI patients and controls was assessed 
by multivariate logistic regression and ROC curve analyses. EV con-
centration and levels of CD62P, CD42a, CD41b, CD40 and CD31 were 
independent significant predictors of STEMI (Table 2). In the training 
cohort, ROC curves indicated a high sensitivity for these markers. An 
aggregate marker including the three most highly discriminating pa-
rameters (EV concentration, CD62P levels and CD42a levels) achieved 
a sensitivity of 90.0% and a specificity of 93.3% (Figure 4A-C). The 
evaluation of the AUC confirmed excellent diagnostic performances 
for these markers (EV concentration, CD62P, CD42a, CD41b, CD40 
and CD31). EV concentration, CD62P, CD42a and the aggregate 
EV marker were not inferior to hs-troponin (Figure 4C). Of note, 
the aggregate EV marker was increased above its cut-off value in 
92.3% of STEMI patients presenting with minimally elevated hs-tro-
ponin < 50 ng/L (a cut-off equalling mean + 1.95*SD of Ctrl values). 
There also was a trend for a higher AUC for the combination of the 
aggregate EV marker and hs-troponin (0.994; 95% CI: 0.980-1.000) 
compared with hs-troponin alone (0.968; CI: 0.927-1.000; Figure 4C).
In the validation cohort, EV concentration, CD62P, CD41b, 
CD42a and CD31 were not inferior to hs-troponin, with AUC ranging 
from 0.865 to 0.979, and sensitivity ranging from 85.0% to 97.5%. 
The aggregate EV marker achieved higher AUC and diagnostic 
performance compared with hs-troponin (P = .036), with a sensi-
tivity/specificity of 100.0%/87.5% (Figure 4B-D). This marker was 
increased in all STEMI patients presenting with minimally elevated 
hs-troponin levels. The combination of the aggregate EV marker and 
hs-troponin showed a higher AUC compared with hs-troponin alone, 
with a sensitivity/specificity of 100.0%/95.0% (P = .021; Figure 4D).
3.6 | Machine learning algorithm model based on 
expression levels of EV biomarkers
The linear combination of all EV surface epitopes is shown in the 
canonical plot (Figure 5A). The model distinguished STEMI patients, 
SA patients and controls. At first screening analysis, only 6 of 30 
STEMI patients were misclassified (5 of them as SA and 1 as con-
trol), resulting in an accuracy of 81.6% (Figure 5B). We then de-
veloped a diagnostic model for STEMI based on the 37 EV surface 
epitopes included in the multiplex using RF classification algorithms 
(Figure 5C,D). The model correctly classified all patients with 100% 
sensitivity, specificity and accuracy. In the validation cohort, this RF 
model achieved a sensitivity/specificity of 75.0%/100.0%. A distinct 
RF model including only the five markers (CD62P, CD42a, CD41b, 
TA B L E  2   Multivariate logistic regression analysis of EV markers and STEMI diagnosis
STEMI vs Ctrl
Ref. STEMI 




























































































































































Note: Association of EV markers and conventional cardiovascular risk factors (including age, BMI, sex, hypertension, diabetes and dyslipidemia), with 
STEMI diagnosis. Serum samples from STEMI patients on presentation to the emergency department were compared with healthy controls (Ctrl) in 
the training cohort (n = 60). Odds ratios (95%-confidence intervals) are shown. Differences were considered significant when P < .05.
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CD40 and CD31) significantly increased in STEMI patients achieved 
91.7% and 90.0% accuracy in the training and validation cohorts, re-
spectively (overfitting bias: 1.7%). This model achieved a sensitivity/
specificity of 80.0%/100.0% in the validation cohort (Figure 5E,F).
4  | DISCUSSION
We have measured multiple EV biomarkers representative of various 
cell types of origin in the blood of patients with acute MI or chronic 
CAD presenting with SA. STEMI patients on presentation to the 
emergency department and to a lesser extent SA patient showed an 
increase in circulating EV numbers, compared to healthy individuals. 
Both STEMI patients and SA patients showed an increase in small-
size EVs (≤150 nm, the size traditionally associated with exosomes), 
whereas only STEMI patients exhibited augmented numbers of me-
dium/large-sized EVs (151-500 nm, the size traditionally associated 
with microvesicles). These results are consistent with the notion 
that release of microvesicles is induced by cellular stress,31 which 
dramatically increases as a result of acute coronary artery occlu-
sion leading to cardiac injury and the inflammatory response to it. It 
should be noted, however, that exosomes and microvesicles cannot 
be precisely discriminated by size.10
The two most highly enriched EV markers in STEMI patients, 
and to a lesser extent in SA patients, were CD62P, a marker of 
platelet activation, and CD42a, another platelet-associated 
marker.32 Two additional platelet-associated markers, CD41b and 
CD31 (the latter also being expressed by activated endothelial 
cells), along with CD40, which may reflect immune activation, 
were increased in STEMI patients. Each of the above markers cor-
related with STEMI diagnosis at multivariate regression analysis. 
They also correlated positively to peak hs-troponin levels and in-
versely to LVEF, suggesting a direct correlation to injury sever-
ity. These findings are in general agreement with previous data 
showing increased numbers of platelet- and endothelial-derived 
EVs in patients with ACS, possibly reflecting the formation of cor-
onary thrombotic occlusions, compared to patients with chronic 
CAD and healthy individuals.12-23 We also found an increase in 
SSEA-4, an antigen expressed by ‘very-small embryonic-like stem 
cells’ that are mobilized from bone marrow after cardiac ischemia 
and participate in endothelial repair,33 at 24-48 hours in STEMI 
patients.
F I G U R E  4   Diagnostic performance 
of EV markers. Diagnostic performance 
of EV concentration (by NTA) and five 
EV markers, compared with hs-troponin 
(*P-values refer to the comparisons of 
the areas under the curves, AUCs) in 
the training cohort and in the validation 
cohort (n = 60 and n = 80, respectively; 
STEMI patients pre-PCI vs. Ctrl). A and B, 
ROC curve analysis for hs-troponin (black 
curve) compared to individual EV markers 
(dashed curves), an aggregate EV marker 
including EV concentration, CD62P MFI, 
and CD42a MFI; red curve), and to the 
combination of the aggregate EV marker 
with hs-troponin (blue curve). C and D, 
AUC (95% Confidence Interval; CI), best 
cut-off (according to Youden's index 
analysis), sensitivity (%) and specificity 
(%), and percentages of patients with 
minimally increased hs-troponin (troponin 
<50 ng/L) showing levels of EV markers 
higher than the respective cut-off. Bold 
characters indicate P-values of diagnostic 
performances showing non-inferiority to 
hs-troponin (AUC for EV markers < AUC 
for hs-troponin; P ≥ .05) or superiority to 
hs-troponin (AUC for EV markers > AUC 
for hs-troponin; P < .05)
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We then looked at the potential diagnostic performance of the 
above EV markers for STEMI. ROC curve analysis revealed a high 
performance for CD62P, CD42a, CD41b, CD40 and CD31, with 
CD62P and CD42a showing non-inferiority to hs-troponin. We also 
aggregated the three most discriminating markers (EV concentra-
tion, CD62P and CD42a) into a single marker, which achieved 90.0% 
sensitivity and 93.3% specificity for the diagnosis of STEMI, with 
non-inferiority to hs-troponin, in the training cohort. The aggregate 
EV marker achieved 100.0% sensitivity at validation. This marker was 
increased in all STEMI patients with minimally increased hs-troponin 
(<50 ng/L) on presentation to the emergency department. Finally, 
a RF model including the full panel of 37 EV surface epitopes, and 
a distinct RF model including the five EV markers that were signifi-
cantly increased in STEMI patients, discriminated these patients and 
controls with high accuracy, as confirmed in the validation cohort.
Unlike previous studies of EV markers in ACS, which focused 
on single markers, or a few cell type-specific markers, we charac-
terized, for the first time, a comprehensive panel of markers, which 
allowed us to identify those markers that achieved highest diag-
nostic accuracy in STEMI patients. By combining three markers, 
diagnostic accuracy was higher than that of individual markers and 
comparable to cardiac-specific hs-troponin I. The power of EV bio-
markers derives from the enrichment of potential protein markers 
which otherwise constitute only a very small proportion of the 
total proteome of body fluids.9 While hs-troponin has improved 
the diagnostic performance of cardiac troponin as a marker for 
ACS, its sensitivity at early stages of myocardial injury is still lim-
ited. Our data indicate that EV derived biomarkers are increased 
at early stages of acute MI, at least in part due to thrombus forma-
tion and ischemia-induced stress to cardiac cells that are still alive, 
whereas the release of troponin reflects cardiomyocyte death. 
Thus, EV biomarkers reflect very early stages of cell stress that 
precede sarcomeric disruption and the release of contractile pro-
tein. Potential advantages and disadvantages of EV profiling versus 
cardiac-specific hs-troponin in the diagnosis of patients with acute 
MI are summarized in Table S1. Obviously, the question about the 
best marker is not the only relevant question. Another question is 
whether a combination of markers may provide an advantage over 
single markers. An important example is the combination of co-
peptin, an acute endogenous stress neuropeptide,34 and troponin. 
F I G U R E  5   Machine learning diagnostic modelling. Diagnostic performance of machine learning models. A, Canonical plot illustrating 
patient distribution according to their diagnosis and to the linear weighted combination of EV surface epitope fluorescence values. Red, 
blue and green circles indicate individual STEMI, SA and control patients. Crosses indicate mean values of (canonical-1; canonical-2) for each 
category. Ellipses include patients with a linear combination coefficient that falls within the mean ± SD (canonical−1+/SD; canonical-2 ± SD). 
B, Confusion matrix reporting real and predicted diagnosis (Ctrl vs. SA vs. STEMI), accuracy, sensitivity and specificity, for the linear 
discriminant analysis (*sensitivity and specificity were calculated using STEMI diagnosis as referral category). C, Representative classification 
tree from the RF based on MFI data (All Epitopes model). D and F, Confusion matrix reporting real and predicted diagnosis (STEMI vs. Ctrl) 
for two distinct random forest (RF) models based either on the full panel of 37 EV markers (All Epitopes) or five EV markers significantly in 
STEMI patients (Selected Epitopes) in STEMI vs. Ctrl. Accuracy, sensitivity and specificity are shown for each model in the training cohort 
(n = 60) and the validation cohort (n = 80). E, Representative classification tree from the RF (Selected Epitopes model)
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While copeptin is non-specific to myocardial injury, it responds 
to an immediate neural trigger with concentrations rising early 
and decreasing gradually over several hours. Adding copeptin to 
cardiac troponin improved the sensitivity and negative predictive 
value for the diagnosis of NSTEMI compared to troponin alone.35 
A similar effect might apply to EV markers, as the combination of 
the aggregate EV marker and hs-troponin showed a higher AUC 
compared with hs-troponin alone, with a sensitivity/specificity of 
100.0%/95.0% for the diagnosis of STEMI (vs. 100.0%/80.0% for 
troponin alone). These data suggest the possibility that EV mark-
ers may play a contributory role in the diagnosis of MI.
Clearly, a technological implementation is still required before 
clinical applications can be envisaged. In this regard, it is worth not-
ing that impressive progress has recently been scored in ultrasen-
sitive detection of circulating exosomes with microfluidic chips. As 
an example, a 3D-nanopatterned microfluidic chip allowed for the 
detection, in 2-μL plasma samples from ovarian cancer patients, of 
exosome subpopulations expressing CD24, EpCAM and FR-α pro-
teins as potential biomarkers for ovarian cancer.36
EV biomarker profiling is emerging as an important general 
approach for precision medicine and personalized treatment. This 
approach could be particularly valuable in the critically ill patient, 
who may show a non-specific increase of hs-troponin.37 Another 
example could be represented by patients undergoing cardiac or 
non-cardiac surgery, owing to the increased risk of periprocedural 
cardiac ischemia.38 A recent study in patients undergoing cardiac 
surgery with cardiopulmonary bypass showed a progressive in-
crease in the number of circulating exosomes collected at 2 hours, 
4 hours and 24 hours after the onset of the cardiopulmonary by-
pass.39 Another study similarly showed a progressive increase in 
the plasma concentrations of exosomes in patients undergoing 
coronary artery bypass graft (CABG). Of note, the increase in 
circulating exosomes was positively and highly correlated with 
troponin.40
Finally, it should be mentioned that, beyond their diagnostic role, 
EV-based biomarkers have predictive value for the prognosis of car-
diovascular disease.41
Regarding methodological issues, we confirmed the technical re-
producibility of the flow cytometric assay used in the present study. 
We also found no major differences between sample ultracentrifuga-
tion and SEC, and between 1-hour or overnight incubation of serum 
supernatant with capture beads. These observations support the 
absence of major methodological confounding factors. Both plasma 
and serum have been used in previous studies; while biobanking of 
plasma may be preferable for studies involving isolation of EV RNA, 
serum also has appropriate uses.42 Platelets can be activated to a 
varying extent during plasma collection, whereas serum sampling in-
volves in vitro platelet activation under standardized conditions. We 
compared serum and plasma samples in a small subset of patients, 
observing a similar EV marker profile. In particular, the five EV mark-
ers that were significantly increased in serum samples from STEMI 
patients compared to controls also were significantly increased in 
plasma. A methodological discussion regarding the more appropriate 
biological fluid is beyond the scope of this study; anyway, the re-
sults of our comparative analysis in a subset of patients suggest that 
serum samples can be used.
A few study limitations need to be addressed. Because of the 
proof-of-principle character of the study, we decided to investigate 
STEMI patients, who exhibit comparatively a clear clinical pheno-
type and hypothetical large changes in circulating EV. The evalua-
tion of unstable angina or NSTEMI patients could be object of future 
studies. Though the study cohorts were small, accurate diagnostic 
models could be developed and validated in larger independent pop-
ulations. Moreover, while healthy individuals were suitable controls 
for this pilot study, unselected control populations including patients 
with chronic CAD, chronic inflammatory diseases, thrombotic dis-
eases, cancer and other disorders would more closely reflect daily 
clinical practice. This point is exemplified by our data, which showed 
larger differences in EV markers in STEMI patients versus healthy 
subjects, compared with STEMI patients versus SA patients.
In conclusion, we have shown that circulating EVs in patients 
with STEMI differ in number, size and surface markers from those 
in healthy subjects, with SA patients showing somewhat intermedi-
ate features. Our findings demonstrate the feasibility of a diagnostic 
assay for early-stage acute MI based on EV biomarkers, with a po-
tential usefulness also in chronic CAD patients. The marker profile 
can be customized to optimize diagnostic accuracy, and the method 
is amenable to full automation.
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